TGF-beta Receptor 1 (TGFβR1) is a serine/threonine protein kinase encoded by the TGFbr1 gene on chromosome 9q22. It is a critical component of the transforming growth factor-beta (TGF-β) signaling pathway, which plays dual roles in both neuroprotection and neuroinflammation. TGF-β signaling is implicated in Alzheimer's disease, Parkinson's disease, and ALS, with complex context-dependent effects on neuronal survival and glial activation.
| Isoform | Expression | Notes |
|---|---|---|
| TGFβR1-A | Ubiquitous | Full-length receptor |
| TGFβR1-B | Neurons | Truncated, kinase-dead variant |
TGFβR1 is a central component of the TGF-beta signaling pathway. The cascade involves:
Amyloid-beta Modulation
Neuroinflammation
Tau Pathology
| Agent | Status | Mechanism |
|---|---|---|
| TGF-β1 | Preclinical | Direct ligand activation |
| Small molecule activators | Discovery | Allosteric TGFβR1 activation |
| Agent | Status | Mechanism |
|---|---|---|
| SB-431542 | Research use | Selective TGFβR1 kinase inhibitor[7] |
| SD-208 | Preclinical | TGFβR1 kinase inhibition |
Tesseur I, et al. Deficient TGF signaling causes reduction in neurogenesis and accumulation of amyloid plaques. J Neurosci. 2006. ↩︎
Wyss-Coray T. TGF-beta pathway as a therapeutic target in neurodegenerative diseases. Neuron. 2016. ↩︎
Hutton SR, et al. TGF-beta SMAD3 signaling mediates neuronal viability and amyloid-beta toxicity. Neurobiol Aging. 2011. ↩︎
McGeer PL, McGeer EG. Glial cell reactions in neurodegenerative diseases: Pathophysiology and therapeutic interventions. Mol Neurobiol. 1998. ↩︎
Deppe M, et al. TGF-beta signaling in Parkinson's disease. Cell Mol Neurobiol. 2022. ↩︎
Endo F, et al. TGF-beta1 mediates inflammatory responses in ALS. Nat Neurosci. 2015. ↩︎
Matsuno Y, et al. TGF-beta type I receptor kinase inhibitor enhances dopaminergic neuron survival in a mouse model of Parkinson's disease. Mol Ther Methods Clin Dev. 2020. ↩︎